SINGULAR IMMUNE, INC.

Biotech · Private

Protein-based immune cell programming platform that delivers manufactured proteins to temporarily reprogram immune cells without genetic modification

Grants
$305K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
6
1 granted · 5 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Novel Protein-Based Platform for In Vivo Chimeric Antigen Receptor (CAR) Generation$304,909
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2980POW GENETIC SOLUTIONS, INC.——
2981QUORUM INNOVATIONS, LLC——
2982NuPeak Therapeutics, Inc.——
2983SINGULAR IMMUNE, INC.——
2984GLOW THERAPEUTICS INC.——
2985TIGATX INC——
2986Whisper Biosciences——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 6
  • Composition And Method Of Use Recombinant Fusion Protein To Generate Car-immune Cellsapplication
  • Composition And Method Of Use Recombinant Fusion Protein To Generate Car-immune Cellsgranted
  • Composition And Method Of Use Recombinant Fusion Protein To Generate Car-immune Cellsapplication
  • Composition And Method Of Use Recombinant Fusion Protein To Generate Car-immune Cellsapplication
  • Composition And Method Of Use Recombinant Fusion Protein To Generate Car-immune Cellsapplication
  • Composition And Method Of Use Recombinant Fusion Protein To Generate Car-immune Cellsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.